Abstract

This research was conducted to investigate the safety and efficacy of using talazoparib to treat advanced breast cancer without human epidermal growth factor receptor 2 gene amplification. We conducted a randomized trial of 80 patients with advanced breast cancer who tested negative for human epidermal growth factor receptor 2 and were treated at our hospital's oncology department between January 2020 and January 2022. Participants were assigned randomly into two groups; talazoparib observation group or the taxine and anthracycline combined chemotherapy control group. Clinical efficacy and adverse reactions were observed after 12 w of continuous treatment. The analysis of data revealed a noteworthy decline in tumor markers carcinoembryonic antigen, cancer antigen 125 and cancer antigen 15-3 (p<0.05) in both the observation and control groups. However, the talazoparib treatment in the observation group showed to be more efficacious in decreasing the tumor markers than the combined chemotherapy in the control group (p<0.05). The life quality measures of all patients in both groups had significantly enhanced after receiving treatment (p<0.05), as per the data analysis. The talazoparib treatment in the observation group caused an even greater improvement in life quality scores, showing significant improvement compared to the combined chemotherapy administered in the control group (p<0.05). Analysis of the data revealed a significantly higher objective response rate in the talazoparib observation group than the chemotherapy control group (p<0.05). However, there was no significant difference in the disease control rate between the groups (p>0.05). Adverse reactions, such as fatigue, nausea, vomiting and decreased white blood cell/platelet count, were observed in both groups. As per the analysis of data, the total incidence of adverse reactions occurred at a significantly higher rate in the talazoparib observation group than the chemotherapy control group (p<0.05). Talazoparib, combined with taxanes and anthracyclines, demonstrated good efficacy and safety for treating human epidermal growth factor receptor 2-negative advanced breast cancer patients. Therefore, it is recommended for clinical use.